These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17255309)

  • 1. Biomarkers for monitoring antiangiogenic therapy.
    Bhatt RS; Seth P; Sukhatme VP
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):777s-780s. PubMed ID: 17255309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
    Rosen MA; Schnall MD
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in clear cell renal cell carcinoma.
    George S; Bukowski RM
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1737-47. PubMed ID: 18062748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
    Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
    Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
    Audenet F; Rouprêt M; Méjean A
    Prog Urol; 2009 Oct; 19(9):596-605. PubMed ID: 19800548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular biomarkers for angiogenesis in clinical oncology.
    Bertolini F; Mancuso P; Shaked Y; Kerbel RS
    Drug Discov Today; 2007 Oct; 12(19-20):806-12. PubMed ID: 17933680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
    Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
    Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
    [No Abstract]   [Full Text] [Related]  

  • 9. A surrogate marker to monitor angiogenesis at last.
    Schneider M; Tjwa M; Carmeliet P
    Cancer Cell; 2005 Jan; 7(1):3-4. PubMed ID: 15652744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and gliomas: current issues and development of surrogate markers.
    Jouanneau E
    Neurosurgery; 2008 Jan; 62(1):31-50; discussion 50-2. PubMed ID: 18300890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?
    Soulières D
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):153-6. PubMed ID: 19512932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal cell carcinoma.
    Rathmell WK; Martz CA; Rini BI
    Curr Opin Oncol; 2007 May; 19(3):234-40. PubMed ID: 17414642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic dosing of chemotherapy: applications in pediatric oncology.
    Stempak D; Seely D; Baruchel S
    Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
    Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
    Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Circulating endothelial cells: biomarkers for monitoring activity of antiangiogenic therapy].
    Farace F; Bidart JM
    Bull Cancer; 2007 Jul; 94 Spec No():S254-9. PubMed ID: 17846012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis inhibition in non-clear cell renal cancer.
    Stadler W
    Clin Adv Hematol Oncol; 2008 Jul; 6(7):507-9. PubMed ID: 18654117
    [No Abstract]   [Full Text] [Related]  

  • 18. [Renal cell carcinoma: the end of a tunnel?].
    Ravaud A; Dilhuydy MS
    Pathol Biol (Paris); 2006 May; 54(4):206-8. PubMed ID: 16530346
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma.
    Bartsch G; Eggert K; Soker S; Bokemeyer C; Hautmann R; Schuch G
    J Urol; 2008 Jan; 179(1):326-32. PubMed ID: 18006013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies.
    Kohandel M; Kardar M; Milosevic M; Sivaloganathan S
    Phys Med Biol; 2007 Jul; 52(13):3665-77. PubMed ID: 17664569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.